I'll direct another question your way, if you don't mind.
Your organization has publicly stated:
...a single public payer national pharmacare program would likely incur significant public costs for limited net benefits to Canadians, based on our research to date.
Can you explain to me why this would be the impression that you've been left with and why your research results would differ from those of the Pharmacare 2020 report?